Shexiang Baoxin Pill for Acute Myocardial Infarction: Clinical Evidence and Molecular Mechanism of Antioxidative Stress
Table 2
Basic information of the included randomized controlled trials.
ID
Sample size (T/C)
Mean age (years)
Diagnostic criteria
Intervention
Comparison
Duration of treatment
Outcomes
Chen ZH 2013
105 (50/55)
T: C:
I
SBP plus RT
RT
8 weeks
②④⑤⑥
Luo Y C 2015
80 (40/40)
T: C:
II
SBP plus RT
RT
4 weeks
⑧
Ge R L 2015
70 (35/35)
T: C:
I
SBP plus RT
RT
8 weeks
②⑤⑥
Yang G L 2013
120 (60/60)
T: C:
II
SBP plus RT
RT
24 weeks
②④⑧
Ma C 2020
90 (45/45)
T: C:
Compliant with II
SBP plus RT
RT
2 weeks
①②⑤⑦⑧
Tian F Q 2016
64 (32/32)
T: C:
II
SBP plus RT
RT
2 weeks
①③④⑧
Wang S S 2016
106 (53/53)
T: C:
Compliant with II
SBP plus RT
RT
2 weeks
①②⑤⑦
Bai X 2020
82 (41/41)
T: C:
Compliant with II
SBP plus RT
RT
2 weeks
②⑤⑧
Wei L N 2018
96 (48/48)
T: C:
Compliant with II
SBP plus RT
RT
2 weeks
①②⑤⑦⑧
Jiang F J 2020
60 (30/30)
T: C:
Compliant with II
SBP plus RT
RT
2 weeks
①⑧
Zhang X T 2017
140 (70/70)
T: C:
Compliant with II
SBP plus RT
RT
NR
①⑧
Xu J 2017
90 (45/45)
T: C:
III
SBP plus RT
RT
12 weeks
②⑥
Yang F 2015
120 (60/60)
T: C:
Compliant with II
SBP plus RT
RT
10 weeks
①③④⑧
Feng B 2020
83 (43/40)
T: C:
II
SBP plus RT
RT
2 weeks
③④
Huang P D 2016
88 (44/44)
T: C:
II
SBP plus RT plus PCI
RT plus PCI
8 weeks
①②③④⑤⑥
Jiang D J 2020
80 (40/40)
T: C:
Compliant with II
SBP plus RT plus PCI
RT plus PCI
2 weeks
②⑦
Xu F L 2018
200 (100/100)
T: C:
Compliant with II
SBP plus RT plus PCI
RT plus PCI
12 weeks
⑤⑥⑧
Lin G Q 2010
59 (30/29)
T: C:
Compliant with II
SBP plus RT plus PCI
RT plus PCI
24 weeks
①②④⑤
Ma R J 2019
116 (60/56)
T: C:
Compliant with II
SBP plus RT plus PCI
RT plus PCI
4 weeks
②④⑧
Note: T: treatment group; C: control group; SBP: Shexiang Baoxin Pill; RT: routine treatment (including oxygen inhalation, vascular dilation, anticoagulation, and thrombolysis); PCI: percutaneous coronary intervention; CPGs: clinical practice guidelines; NR: not reported; I: diagnostic criteria of AMI developed by the World Health Organization; II: diagnostic criteria of AMI developed by the Chinese Cardiovascular Society; III: diagnostic criteria of AMI developed by the American Heart Association and American College of Cardiology; ①: clinical efficacy rate; ②: cardiac function; ③: oxidative stress; ④: AMI evaluation index; ⑤: inflammatory factors; ⑥: blood lipid level; ⑦: vascular endothelial function; ⑧: complication rate.